Mylan to buy Swedish drugmaker Meda in $7.2 billion deal

Moody's Affirms Ratings of Mylan (MYL) Amid Meda Acquisition Deal

Moody's Investors Service affirmed the Baa3 senior unsecured ratings of Mylan N.V. and Mylan Inc (Nasdaq: MYL). This follows the announcement that Mylan has made an offer to acquire Meda AB for $9.9 billion in cash and stock. The outlook is stable.

"The acquisition of Meda will meaningfully increase Mylan's leverage -- to around 4.0x debt/EBITDA from around 2.5x." Said Moody's Senior Vice President, Jessica Gladstone. "However, there was substantial cushion built in to Mylan's Baa3 rating as we had anticipated that the company would continue to pursue large acquisitions... More

Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal

Mylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More

Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim

After the 4Q15 miss and announcement of the deal to acquire Meda Guggenheim analyst, Louise Chen, remains on the sidelines and kept her Neutral rating on Mylan (NASDAQ: MYL) shares. This acquisition makes strategic sense, but Meda (3% topline, 5% EBITDA growth) does not enhance MYL's sales and earnings profile. This is important ahead of potential generic competition for Epipen in 2H16. No change to... More

RBC Capital Views Mylan's (MYL) Meda Purchase as Desperate - PT to $58

RBC Capital reiterated a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $58.00 (from $60.00), following the company's announcement that they will acquire Meda for $9.9 billion. Separately, MYL missed 4Q. Neither will help the stock and this deal feels desperate in RBC's... More